What tirzepatide is. And where it comes from
Tirzepatide is a synthetic 39-amino-acid peptide. Its scaffold is based on the GIP (glucose-dependent insulinotropic polypeptide) sequence, with key substitutions that confer GLP-1 receptor agonism on the same molecule. The modifications also confer resistance to DPP-4 cleavage and prolong half-life to roughly five days, enabling once-weekly dosing.
Tirzepatide is the first approved dual-receptor incretin agonist, it activates both GIP and GLP-1 pathways in a single molecule, which appears to produce greater weight loss than either pathway alone.
Mechanism, in plain English
Tirzepatide activates two incretin receptors simultaneously:
- GIP receptor. GIP is secreted by K cells in the duodenum in response to food. It enhances insulin secretion, modulates lipid handling, and contributes to adipose-tissue biology. GIP signaling in the CNS also affects appetite and energy expenditure.
- GLP-1 receptor. Glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, and central satiety signaling, the same pathway semaglutide targets.
The dual activity is what distinguishes tirzepatide from single-receptor GLP-1 agonists. The additive receptor activation produces greater insulinotropic and weight-loss effects than either pathway alone. As demonstrated in head-to-head trials.
Want all 24 weight loss and metabolism compounds in one place?
The Peptexa Weight Loss and Metabolism guide covers every compound in this category, mechanism, evidence level, and FDA status for each.
What the trial evidence shows
Two trial programs define tirzepatide's evidence base:
SURPASS-2 (T2D head-to-head). NEJM 2021, Davies et al.: 1,879 adults with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg weekly. At 40 weeks, 15-mg tirzepatide reduced HbA1c by 2.30 percentage points vs 1.86 for semaglutide, with body-weight reductions of 12.4 kg vs 6.2 kg.
SURMOUNT-1 (chronic weight management). NEJM 2022, Jastreboff et al.: 2,539 adults with BMI ≥30 or ≥27 with comorbidity. Mean body-weight reductions at 72 weeks: 16.0%, 21.4%, and 22.5% across tirzepatide doses vs 2.4% placebo. Among the largest magnitudes of weight loss reported in any phase 3 obesity pharmacotherapy program.
Mean body-weight reduction of 22.5% at the highest tirzepatide dose in SURMOUNT-1 represents the largest effect size reported in any late-stage obesity pharmacotherapy trial to date.
FDA status (this month)
Tirzepatide is FDA-approved under two brand names: Mounjaro (subcutaneous injection, type 2 diabetes mellitus, 2022) and Zepbound (subcutaneous injection, chronic weight management in adults with BMI ≥30 or ≥27 with comorbidity, 2023; indication expanded in 2024 to include moderate-to-severe obstructive sleep apnea in adults with obesity). Last reviewed 2026-08-09.
Common synonyms researchers use
Tirzepatide · LY3298176 (early Lilly designation) · GIP/GLP-1 RA · dual incretin agonist (class label) · Mounjaro, Zepbound (brand references).
Safety & adverse-event landscape
Most common adverse effects across SURPASS and SURMOUNT were gastrointestinal: nausea, vomiting, diarrhea, constipation, dyspepsia, mild-to-moderate, dose-related, attenuating over time. The product label carries a boxed warning for thyroid C-cell tumors (based on rodent carcinogenicity data), plus warnings for pancreatitis, gallbladder disease, and hypoglycemia risk with insulin secretagogues. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Always consult a qualified healthcare provider.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Weight Loss & Metabolism reference
24 compounds. Mechanism, evidence level, and FDA status for every one. Free PDF, no email required.
Get the Weight Loss & Metabolism Guide →